Related Experiment Video
Updated: May 17, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Rivaroxaban: a novel anticoagulant.
1Department of Medicine, S.M.S Medical College, Jaipur, Rajasthan, India. dralimuzaffar@gmail.com
Indian Journal of Medical Sciences
|October 12, 2012
Summary
For over 50 years, warfarin dominated anticoagulation. This review examines rivaroxaban, a direct factor Xa inhibitor, as a significant new competitor challenging warfarin's long-standing clinical use.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Warfarin has been the primary oral anticoagulant for over five decades since its introduction in 1940.
- No other anticoagulant has achieved comparable clinical dominance until recent advancements.
- The landscape of anticoagulation is evolving, with new agents emerging.
Purpose of the Study:
- To review the clinical profile of rivaroxaban.
- To position rivaroxaban as a key competitor to warfarin.
- To discuss the impact of novel anticoagulants on established therapies.
Main Methods:
- Literature review of clinical studies and pharmacological data.
- Comparative analysis of warfarin and rivaroxaban efficacy and safety.
- Examination of the mechanism of action for direct factor Xa inhibitors.
Main Results:
- Rivaroxaban represents a significant advancement in anticoagulation therapy.
- Direct factor Xa inhibitors offer an alternative to traditional vitamin K antagonists.
- Emerging anticoagulants are beginning to challenge warfarin's market share.
Conclusions:
- Rivaroxaban is a prominent direct factor Xa inhibitor.
- The development of novel anticoagulants marks a new era in anticoagulant therapy.
- Warfarin's long-standing dominance is facing unprecedented competition.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...